Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Ovarian Neoplasm: early-phase trial registry

1 of 8 indexed Ovarian Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 1 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Ovarian Neoplasm: 8 US clinical trials tracked, 1 recruiting.

Ovarian Neoplasm is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Southeastern Gynecologic Oncology, running 1 of these trials.

Enrollment posture brief

Registry condition ovarian-neoplasm

OPEN 1 | RECR 13% | LATE 1 | EARLY 3 | RANK #2176 | SPON 1

Nearest open-share peer: Acute Respiratory Infection (13% recruiting · 8 trials)

Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%Ovarian Neoplasm (this)13%
Open-enrollment share among volume-matched conditions near Ovarian Neoplasm

Ovarian Neoplasm lists 1 open slots (13% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Ovarian Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Ovarian Neoplasm is recruiting below its size-band peers.

    1 of 8 indexed trials (12.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Ovarian Neoplasm trials is spread across many organizations.

    Southeastern Gynecologic Oncology accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Ovarian Neoplasm enrolment sits around 120 participants.

    Median target enrolment is 120 among the 8 trials that report a genuine target (sentinel values excluded). 4 of those (50%) plan for fewer than 100 participants.

  4. Ovarian Neoplasm research is mostly interventional.

    7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21Phase 31

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 1

Named interventions

Most-linked intervention names on Ovarian Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
2 trials
Study of High Risk Factors Procedure
1 trials
TAK-165 Drug
1 trials
Omega-3 fatty acid Dietary supplement
1 trials
Supportive Care Procedure
1 trials
BT8009 Drug
1 trials
POSTCare Survivorship transition process Behavioral
1 trials
Nab-paclitaxel 100 mg/m^2 Drug
1 trials

US sites by state

Facility locations filed on Ovarian Neoplasm trials. A trial with sites in several states counts in each.

Texas 3 trials
Florida 3 trials
Colorado 3 trials
Arizona 3 trials
Illinois 2 trials
Georgia 2 trials
California 2 trials
Tennessee 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Ovarian Neoplasm page

8 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ovarian Neoplasm condition card totals 8 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.